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BACKGROUND: We examined the association between active and passive smoking and lung cancer risk and the population
attributable fraction (PAF) of lung cancer due to active smoking, in the Norwegian Women and Cancer Study, a nationally
representative prospective cohort study.
METHODS: We followed 142,508 women, aged 31–70 years, who completed a baseline questionnaire between 1991 and 2007,
through linkages to national registries through December 2015. We used Cox proportional hazards models, to estimate hazard
ratios (HRs) with 95% confidence intervals (CIs). We calculated PAF to indicate what proportion of lung cancer cases could have
been prevented in the absence of smoking.
RESULTS: During the more than 2.3 million person-years of observation, we ascertained 1507 lung cancer cases. Compared with
never smokers, current (HR 13.88, 95% CI 10.18–18.91) smokers had significantly increased risk of lung cancer. Female never
smokers exposed to passive smoking had a 1.3-fold (HR 1.34, 95% CI 0.89–2.01) non- significantly increased risk of lung cancer,
compared with never smokers. The PAF of lung cancer was 85.3% (95% CI 80.0–89.2).
CONCLUSION: More than 8 in 10 lung cancer cases could have been avoided in Norway, if the women did not smoke.
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BACKGROUND
Lung cancer is the third most common cancer in women
worldwide.1 Active smoking is the main cause of lung cancer. The
incidence of lung cancer among women in Western Europe has
plateaued in recent years.2 In Norway, the incidence rate for lung
cancer in women decreased in 2017. If this reduction continues,
2015 will be the top year with the highest incidence of lung cancer
among Norwegian women, with a rate of 53.1 per 100,000.3 In 2017,
the incidence rate of lung cancer among Norwegian women were
52.0 per 100,000.4 The incidence trend of lung cancer among
Norwegian women is similar to that in Denmark, but steeper than
those observed in Sweden and Finland.5
Among Norwegian women, the smoking prevalence increased
sharply from 1920 and towards 1950 when 20% of women were
smokers.6 The prevalence of daily smoking in Norwegian women
peaked at 37% around 1970.6 Today, 12% of Norwegian women
are daily smokers.7 However, lung cancer is also a significant
health problem among those exposed to passive smoking.8,9 In
Northern Europe, approximately 26% of lung cancer cases occur in
women who have never smoked.10 The IARC Monograph from
2004, The US Surgeon General and the latest World Cancer Report
state that exposure to involuntary smoking increases lung cancer
risk by ~20–30%.1,11,12 Other known risk factors for lung cancer are
exposure to asbestos, radon, polycyclic aromatic hydrocarbons,
and emissions from household combustion of coal.2
Few prospective cohort studies have been able to study both
active and passive smoking, and the lung cancer risk they confer
among women.
We utilised the Norwegian Women and Cancer Study, a
nationally representative prospective cohort, to estimate the risk
of lung cancer associated with active and passive smoking.
Furthermore, we estimated the number of lung cancer cases that




The Norwegian Women and Cancer Study cohort profile has been
previously described in detail.13 The NOWAC Study is initiated
from the University of Tromsø–The Arctic University of Norway.
Briefly, the Central Population Register selected a random sample
of women according to the year of birth. Subsequently, an
invitation to participate in the study together with a baseline
questionnaire and a pre-stamped return envelope enclosed was
mailed to each woman. All women gave informed consent
(https://site.uit.no/nowac/). The National Data Inspectorate and
the Regional Committee for Medical Research Ethics approved
the study.
Women who completed a questionnaire during three waves of
data collection: 1991–1992, 1996–1997, and 2003–2007 (172,478),
were included. The overall response rate was 52.7%. We excluded
women with prevalent cancer (n= 6664), those who emigrated
(n= 64), or died before the start of follow-up (n= 10), those with
an age at the exit that was below age at recruitment (n= 32),
those with missing information on smoking status (n= 590), and
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never smokers with missing information on passive smoking (n=
10,879). Finally, we excluded those with missing information on
the covariates education and alcohol consumption (n= 11,731).
Altogether, 349 women with lung cancer were excluded in this
process. The cohort comprised 142,508 women and 1507 lung
cancer cases.
Exposure information
As described previously14 the questionnaire included a detailed
assessment of smoking habits, if their parents smoked during
childhood, if they lived with a smoker as adults, physical activity,
alcohol consumption as well as the height and current weight
(which were used to compute body mass index (BMI) as weight in
kilograms divided by the square of height in metres). The
questionnaires asked if the women had ever been smoking, and
those answering ‘yes’ were asked for the number of cigarettes
smoked daily at different age intervals. Subsequently, they were
asked if they smoked on a daily basis at present. We categorised
ever smokers according to current and former smoking status, age
at smoking initiation, smoking duration, the average number of
cigarettes smoked daily, pack-years of smoking (i.e., number of
cigarettes smoked per day, divided by 20, multiplied by the
number of years smoked), all at enrolment. Former smokers were
classified according to years since quitting smoking. All women
who were neither current nor former smokers were classified as
never smokers. Among never smokers, those who reported that
their parents smoked during childhood or they lived with a
smoker as adults were classified as passive smokers. We calculated
average alcohol consumption in g/day among drinkers based on
the content of pure alcohol in different beverages and usual
portion sizes in Norway.
Follow up
As previously described15 we followed the women through
linkages to the Cancer Registry of Norway and the Norwegian
Central Population Register to identify all cancer cases, and
emigrations and deaths, respectively, using the unique 11-digit
national personal identification number. We calculated person-
years from the start of follow-up to any incident cancer diagnosis
(except basal cell carcinoma), emigration, death or the end of
follow-up (31 December 2015), whichever came first. We classified
lung cancer cases according to the original codes in the
International Classification of Diseases, Seventh Revision.
Statistical analysis
We calculated the age standardised (WHO 2000–2025) incidence
rate of lung cancer overall by smoking status.16
We stratified all models by recruitment sub-cohort (1991–1992,
1996–1997 and 2003–2007) to control for potential differences at
the three recruitment waves. As previously described15 we used
the Cox proportional hazards model, with age as the underlying
time scale, to estimate crude and multivariate-adjusted hazard
ratios (HRs) and 95% confidence intervals (CIs) for the associations
between lung cancer and different measures of smoking
exposure. Smoking exposure was defined using smoking status
at cohort entry (never, passive, former, current or ever); for women
who had ever smoked, further exposures were defined using
smoking duration (1–9, 10–19, 20–29, ≥30 years), number of
cigarettes smoked per day (1–9, 10–19, ≥20), number of pack-
years of smoking (1–5, 6–15, >15) age at smoking initiation (≤ 17,
>17–20, >20) years), and for former smokers: years since quit
smoking (1–9, 10–20, > 20 years). The reference group is never
active, never passive smokers throughout the manuscript, unless
otherwise noted.
We included covariates that changed the HR estimate by at least
5% as confounders of the association between smoking and
lung cancer.17 We included the following variables in the
final multivariable models; age at enrolment, years of education
(<10, 10–12, ≥13 years) and average alcohol consumption, in grams
of alcohol per day (0, ≤4, 5–9, ≥10). We performed similar analyses
without excluding participants with missing information on the
covariates education and alcohol consumption. Indicator variables
specific to missing in education and alcohol were used, after
checking that these indicators were not statistically associated with
risk of lung cancer. The other variables tested were BMI and physical
activity, which did not change the estimates by at least 5%. Women
who reported no alcohol consumption and those answering
“seldom or never” had their alcohol consumption set to 0.
We tested for linear trends across categories of smoking exposure
variables, excluding never smokers, by assigning a median score in
order to account for the distance between categories, treating the
variable as continuous in the analysis. We tested and found that the
criteria for the proportional hazards assumption were met using
Schoenfeld residuals (data not shown).
We calculated PAFs (%) to indicate what proportion of lung
cancer cases could have been prevented in the population in
absence of smoking. We used the formula PAF= Pe (RRe− 1)÷
(Pe × RRe+ [1− Pe], where the notation Pe= the proportion of
persons in the population exposed to the risk factor (i.e., ever
smokers) and RRe= the relative risk in the exposed compared with
the unexposed group estimated through the HRs (ever compared
with never active never passive smokers).18 We calculated the
two-sided 95% CIs for the PAFs using the PUNAF Stata module.19
We performed analyses using STATA version 15.0 (Stata Corp.)
and considered two-sided P-values ≤ 0.05 as statistically significant.
RESULTS
During the more than 2.3 million person-years of observation
(mean follow-up time was 15.9 (±6.5) years, we ascertained 1507
lung cancer cases. At enrolment, the mean age of the participants
was 48.9 (±8.3 s.d) years. Of these women, 69.3% (n= 98 795)
reported to be ever (current 32.2%, former 37.1%) smokers, with
14.8 (± 12.9 s.d) years of smoking. Former smokers quit smoking
16.9 (±9.8 s.d) years ago. Among never smokers 17.6% (n= 25
082) reported to be passive smokers. Altogether 77.9% (n= 114
191) of the women reported to be alcohol drinkers, with a mean
alcohol consumption of 3.9 (±6.1 s.d) grams per day. Mean years of
education was 12.4 (±3.5) among the women. The age-
standardised incidence rate for lung cancer among never, passive,
and ever smokers was 13.4, 20.0, and 87.1 per 100,000 person-
years respectively.
Table 1 shows that never and passive compared with current
smokers, were more likely to have higher education, higher BMI
and less likely to consume alcohol. Adenocarcinoma was the most
common histological lung cancer type in both never and ever
smokers. Squamous cell (15%)- and small cell (23%) carcinoma
were found most commonly in current smokers. These two
histological subtypes were almost absent in never smokers
(Table 1).
Table 2 shows that when compared with never smokers,
current smokers had a lung cancer hazard ratio that was almost
14-fold (HR 13.88, 95% CI 10.18–18.91) higher. For ever smokers
there was a dose response for the different smoking exposures
(smoking duration, cigarettes smoked per day and pack-years, all
p-trend <0.001). The highest hazard ratios for lung cancer
among ever compared with never smokers, was a 21 fold
increase in risk of lung cancer among those who smoked > 20
cigarettes per day (HR 21.66, 95% CI 16.54–28.37) and for those
who smoked > 15 pack-years (HR 21.24, 95% CI 15.52–29.06).
Female never smokers exposed to passive smoking had a hazard
ratio of 1.34 (95% CI, 0.89–2.01) compared with never smokers
without any passive exposure.
The overall results remained materially the same when we
included participants with missing information on the covariates
education and alcohol consumption (data not shown).
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Table 3 shows that compared with current smokers, former
smokers who had quit smoking 1–9 years ago had a 63% (HR 0.37,
95% CI 0.30–0.45) reduced risk, while those who had quit smoking
>20 years ago had a 89% (HR 0,11, 95% CI 0.08–0.15) reduced risk
of lung cancer (all p-trend < 0.001).
The PAF of lung cancer was 85.3% (95% CI 80.0–89.2) for ever
smoking.
DISCUSSION
In this nationally representative cohort of middle-aged Norwegian
women, we found that never smokers exposed to passive smoking
had a non-significantly higher risk of lung cancer compared with
never smokers. More than eight in ten lung cancer cases are
attributable to active smoking.
The proportion of 32.2% current smokers in our cohort is higher
compared with current smokers among Norwegian women
through our follow-up. The higher proportion of current smokers
in our cohort could be a result of a higher proportion of smokers
in the middle-aged women included in the study, compared with
female smokers in the Norwegian population through our follow-
up.7 In addition, there was a higher response in recruitment in the
NOWAC study among women in northern Norway, which has the
highest proportion of smokers in Norway.20
It is reassuring that although we have a relative small group of
never smokers the age-standardised incidence rates for lung
cancer that we found for never smokers not exposed to passive
smoking, is in accordance with the 14.3 per 100 000 reported
among never smokers not exposed to passive smoking in ‘The UK
Million Women Cancer Study’.21
We found adenocarcinoma to be the most frequent histological
subtype in both ever and never smokers, in accordance with other
prospective cohort studies from the UK, the US and Norway.21–23
Table 1. Selected characteristics of the study sample by smoking
status, in the Norwegian Women and Cancer Study, 1991–2015, (N=
142 508).



































































































Lung cancer overall 43 53 329 1,082
Adenocarcinomad (%) 26 (61) 34 (64) 173 (52) 459 (42)
Squamous cell
carcinomad (%)
1 (2) 2 (4) 35 (11) 159 (15)
Small cell lung
cancerd (%)
2 (5) 2 (4) 45 (14) 246 (23)
Other nsclcd,e (%) 12 (28) 13 (24) 59 (18) 138 (13)
Large cell
carcinomad (%)
1 (2) 2 (4) 8 (2) 22 (2)
Excludedd,f (%) 1 (2) 0 (0) 9 (3) 58 (5)
aPassive smokers include never smokers who lived with a smoker in their
childhood and/or live with a smoker at enrolment of the study.
bNA (not applicable).
cBody mass index; weight in kilograms divided by the square of the
heights in metres.
dThe percentage of each histological subtype in each column is the
percentage of the subtype of lung cancer overall in that column.
eOther nsclc; not specified non small cell lung carcinoma.
fExcluded; Other or not otherwise specified carcinoma.
Table 2. Crudea- and multivariateb adjusted hazard ratio (HR)
estimates for lung cancer with 95% confidence intervals (CIs) for




Cases (n) HRa (95% CI) HRb (95% CI)
Neverc 43 1.00 (ref ) 1.00 (ref)
Passive 53 1.33 (0.89–2.01) 1.34 (0.89–2.01)
Former 348 3.81 (2.77–5.23) 3.69 (2.68–5.09)
Current 1139 15.44 (11.37–20.98) 13.88 (10.18–18.91)
Ever 1464 7.67 (5.66–10.41) 6.80 (5.00–9.24)
Smoking duration in ever smokersd
1–9 231 4.58 (3.29–6.39) 4.16 (2.98–5.82)
10–19 203 4.24 (3.05–5.91) 4.22 (3.02–5.90)
20–29 429 9.26 (6.75–12.71) 8.55 (6.20–11.77)
≥30 595 18.11 (13.25–24.74) 16.48 (12.02–22.60)
P-trende <0.001 <0.001
Cigarettes smoked per day in ever smokersd
1–9 376 4.46 (3.57–5.58) 4.28 (3.42–5.37)
10–19 767 13.16 (10.65–16.28) 12.17 (9.81–15.10)
>20 125 23.07 (17.70–30.06) 21.66 (16.54–28.37)
P-trende <0.001 <0.001
Pack-years in ever smokersd
1–5 199 4.01 (2.89–5.57) 3.81 (2.73–5.31)
6–15 429 8.40 (6.13–11.50) 7.90 (5.74–10.86)
>15 671 22.52 (16.53–30.69) 21.24 (15.52–29.06)
P-trende <0.001 <0.001
Age at smoking initiation in ever smokersd
>20 334 6.33 (4.84–7.62) 5.76 (4.55–7.28)
17–20 739 9.95 (8.04–12.31) 9.08 (7.31–11.27)
≤17 315 6.07 (4.84–7.61) 5.70 (4.53–7.17)
P-trende <0.001 <0.001
aAdjusted for age.
bAdjusted for age, duration of education and alcohol consumption, all at
enrolment.
cNever-active, never-passive smokers as reference group.
dThe sum of cases in each interval in smoking duration, cigarettes day,
pack-years and age at smoking initiation does not sum up to the total
number of cases in ever smokers because of missing values.
eTest for trend excluding never smokers.
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Our study confirms a consistent, strong dose-response relation-
ship between active smokers and lung cancer risk, as has been
previously shown in other cohort studies.22,24 We found an inverse
dose response with time since quit smoking and risk of lung
cancer among former smokers in accordance with prior findings.22
The risk of lung cancer in our study decreased almost to the level
of a never smoker 20 years after quitting. Another cohort study,
with 89 000 female participants of whom 144 former smokers
were diagnosed with lung cancer, observed that the risk of lung
cancer decreased to almost the level of a never smoker already 15
years after quit smoking.24
The magnitude of our estimate for lung cancer risk due to passive
smoking was higher than those reported in two expert reports.11,12
The studies included in these reports ended their follow-up in the
beginning of this century or before. Since the lag-time to develop
lung cancer is several decades, the women in our study have had
until 2015 to develop the disease, so this discrepancy is as expected.
One limitation with our and other studies on passive smoking and
risk of lung cancer is lack of power due to few cases among never
smokers. A 2018 meta-analysis included a total of 1996 lung cancer
cases from seven cohort studies, which reported between 11 and
136 lung cancer cases among passive smokers.25 Among the cohort
studies included in the meta-analysis, the estimates for lung cancer
risk among passive smokers was statistically significant in only one
study which was from Korea, published in 1999. The Korean study
included close to 160,000 female participants, and 79 lung cancer
cases among women exposed to passive smoke from their spouse.
They observed an increased risk of 90% among female passive
smokers.26 Among the cohort studies in the meta-analysis, one of
the studies were from Europe. The 2005 European study included in
the meta-analysis comprised 95,947 women, among whom 70 were
diagnosed with lung cancer; did not find any significantly increased
risk of lung cancer in women exposed to passive smoke at home.27
One of the two studies from the US included in the meta-analysis,
including 76,304 participants and follow-up until 2009, observed
152 lung cancer cases among never smokers. The US study found
no association between exposure to passive smoking and lung
cancer risk.22 Among the cohort studies included in the meta-
analysis, only the study from Korea26 and one of the two studies
from the US22 adjusted for occupation. In the ‘UK Million Women
Study’, with follow-up through 2011, there were 1469 cases among
the 634,039 never smokers, but exposure to passive smoking as a
child and/or as adult was not associated with any significantly
increased risk of lung cancer.21 This study did not adjust for
occupation.
The PAF for ever smoking in our study corresponds to the 78%
estimated for US white women. This study, published in 2014, had
173 lung cancer cases among the 5487 white women in the
study.28 Similarly, the PAF value for ever smoking UK women, was
estimated to be 80% in 2010. The PAF value in the UK women was
based on indirect estimation from national vital statistics.29 To our
knowledge, we are the first to report this high PAF for women
based on individual data from a random nationwide sample. It
shows that former and current smoking is causing more lung
cancer among women than previously anticipated. We attribute
this to the fact that we have follow-up until 2015. Furthermore, we
expect that the PAF due to smoking among women may increase
with a longer follow-up in future studies.
Strengths and limitations of the study
The most important strength of our study is that it is a nationally
representative cohort study allowing us to calculate the PAF of
lung cancer due to smoking for women in their middle-age, based
on individual data. From our previous studies14,15,30,31 we know
that the smoking exposure and the cancer incidence13 reflect
known smoking patterns6 and cancer incidence32 for Norwegian
women. Thus, we are confident that our cohort is representative of
the Norwegian female population, born between 1927 and 1965,
both according to smoking exposure and outcome of our study.
Other strengths are the high proportion of both current and
former smokers, and a virtually complete follow-up through the
National population-based registries. The lag period between
smoking initiation, usually in adolescence and the end of follow-
up resulted in a large number of cases, which gave us the ability to
examine the dose response association and risk in both former
and current smokers. Another strength is that we focus our PAF
estimates on the comparison between ever versus never smokers
which is the most interesting figure in a public health perspective.
Also, only never smokers could possibly change smoking status
during follow-up. Since very few Norwegian women start to
smoke after age 30 and the mean age at enrolment of this study is
more than 40 years, we are confident that the possible changes in
smoking status among the never smokers during follow-up did
not influence our PAF estimates.33 The limitations include lack of
complete information on smoking status. We excluded nearly
11,000 women because of missing information due to passive
smoking. We have few lung cancer cases among never smokers,
resulting in a lack of statistical power. The prevalence of smoking
among women in Norway continuously decreased during our
follow-up (1991–2015). As we used baseline smoking exposure,
our risk estimates and the PAF could be underestimated. Our
current smokers at enrolment are during follow-up a mix of
current and former smokers because some quit smoking. There-
fore, our risk estimates for lung cancer among current smokers are
actually not for current smokers. If no current smokers quit
smoking during follow-up, our risk estimates would have been
higher than we observed. Additionally, we lack information
regarding smoking exposed occupations such as workers in bars
and restaurants. Participants exposed to work related tobacco
could have been classified as never smokers. This could reduce
our risk estimates for passive and active smokers. Improvements
for future studies include focus on the questionnaires regarding
passive smoking and occupation, as well as smoking status.
As pointed out by Jha,34 the full effects of smoking can take up to
50 years to measure in individuals, and up to 100 years to measure
in a population. We may therefore expect, that in Norway, where
relatively many women have been smokers, our relatively high PAF
may become even higher in future studies. Norway was also one of
the first countries to introduce restrictive rules for tobacco control
when ‘The Norwegian Tobacco Act’ entered into force in 1975.35
Milestones in ‘The Norwegian Tobacco Act’ are: Since 1988, there
has been legal protection from exposure to tobacco smoke in
workplaces, and since 2004, even a complete ban on smoking in
bars and restaurants, and the legal age to buy tobacco was
increased to 18 years in 1996. Our study shows that tobacco control
campaigns and restrictions should continue to be a high priority in
all countries with a high smoking prevalence. Further, smoking
cessation programme among middle-aged women, should be given
Table 3. Crudea- and multivariateb adjusted hazard ratio (HR)
estimates for lung cancer with 95% confidence intervals (CIs) for
former smokers according to years since quit smoking, the Norwegian
Women and Cancer Study, 1991–2015.
Cases HRa (95% CI) HRb (95% CI)
Current smokers 1.00 (ref ) 1.00 (ref )
1–9 years 90 0.34 (0.28–0.42) 0.37 (0.30–0.45)
10–19 years 56 0.16 (0.12–0.21) 0.17 (0.13–0.23)
>20 years 46 0.11 (0.08–0.14) 0.11 (0.08–0.15)
P-trend <0.001 <0.001
aAdjusted for age.
bAdjusted for age, duration of education and alcohol consumption, all at
enrolment.
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high priority. In summary, more than eight in ten lung cancer cases
among middle-aged women in Norway could have been prevented
if the women did not smoke.
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